These Patients Got the Cure. Then It Went Away.news2025-09-22T22:35:25+00:00September 22nd, 2025|The New York Times|
Sarepta Refuses FDA Request to Stop Shipping Muscular Dystrophy Drug Elevidysnews2025-07-19T00:53:42+00:00July 19th, 2025|The New York Times|
Scientists May Be Able to Make Grapefruits Compatible With Medications They Currently Interfere Withnews2025-01-10T16:36:58+00:00January 10th, 2025|The New York Times|
First Day of a ‘New Life’ for a Boy With Sickle Cellnews2024-09-16T18:49:38+00:00September 16th, 2024|The New York Times|
F.D.A. Approves 2 Sickle Cell Treatments, One Using CRISPR Gene Editingnews2023-12-09T02:22:13+00:00December 9th, 2023|The New York Times|
New Sickle Cell Therapies Will Be Out of Reach Where They Are Needed Mostnews2023-12-08T22:46:17+00:00December 8th, 2023|The New York Times|
Sickle-Cell Treatment Created With Gene Editing Wins U.K. Approvalnews2023-11-16T22:23:56+00:00November 16th, 2023|The New York Times|
Panel Tells F.D.A. That CRISPR Sickle Cell Cure Is Safe Enough for Patientsnews2023-10-31T21:21:11+00:00October 31st, 2023|The New York Times|
F.D.A. Experts Will Vote on Safety of a Cure for Sickle Cell Diseasenews2023-10-30T20:19:43+00:00October 30th, 2023|The New York Times|
Suddenly, It Looks Like We’re in a Golden Age for Medicinenews2023-06-23T15:29:07+00:00June 23rd, 2023|The New York Times|
